Grain Hunting on December 2nd | Open Source Securities research reports pointed out that humanwell healthcare (600079.SH) three products were first included in medical insurance, expected to contribute new performance quantities, maintaining a "buy" rating. In November 2024, Yichang humanwell injected Propofol sodium, Hydrocodone hydrochloride sustained-release tablets, and Chloramphenicol tablets were first included in the medical insurance catalog. The inclusion of these three products in medical insurance will continue to increase the market accessibility and sales potential of pharmaceuticals, further diversifying the company's profit growth points. Through continuous innovation and high-quality production, the company is expected to continue to expand its market share and enhance its competitive position in the pharmaceutical industry. The inclusion of the company's products in medical insurance this time once again increases the company's profit growth points, and anesthesia products are expected to quickly increase production. With the steady progress of shareholders' restructuring, the leading anesthetic is expected to usher in a valuation repair.